



ASX RELEASE

Company Secretary appointed

BRISBANE, Australia, 11 April 2006: Peplin Limited (ASX:PEP) today announced the appointment of David Smith as Company Secretary.

Mr Smith has been with Peplin for almost two years in the role of Financial Controller. Prior to joining Peplin David had a variety of roles in a number of organisations in Australia and the UK. These included corporate accounting and analytical roles for businesses in the energy sector and working in public practice for a Big 4 chartered accounting firm. He is a chartered accountant, holds a Bachelor of Commerce degree and has completed post graduate studies in finance and accounting.

In addition to his role as company secretary, David will continue as Financial Controller with responsibility for Peplin's accounting, treasury and administration. He is also appointed as company secretary for each subsidiary within the Peplin group of companies.

Further information:

Michael Aldridge
Managing Director & CEO
Tel: 07-3250 1200
michael.aldridge@peplin.com

ABOUT PEPLIN

Peplin is focused on the development and commercialisation of prescription human therapeutic products for the treatment of cancer. Its lead compound is PEP005, the first in a new class of investigational agents. Peplin's lead product is PEP005 Topical, which is being studied in clinical trials for the treatment of actinic keratosis (AK) (a pre-cancerous lesion) and non-melanoma skin cancer (NMSC). PEP005 Topical works by a powerful mode of action, directly killing most cancer cells and then recruiting and activating the local immune system to clean-up these dead cancer cells and kill any remaining cancer cells. PEP005 Topical is potentially a rapidly acting and cosmetically attractive non-surgical topical treatment for AK and NMSC. Peplin's product development activities are supported by the Australian Federal Government under its Pharmaceuticals Partnerships Program.

Peplin's earlier stage pipeline is targeted at leukemia (a blood borne cancer) using its lead compound PEP005 in an intravenous formulation (PEP005 IV) and bladder cancer using an intracavitary or intravesical formulation (PEP005 IC). PEP005 has demonstrated selective and potent anti-leukemia activity in pre-clinical disease models. PEP005 induces apoptosis in leukemia cells via the activation of PKC delta. Peplin holds global proprietary rights for PEP005 Topical and other oncology applications of PEP005. Its research portfolio of EPUFA compounds opens additional potential opportunities in cancer and pain.